Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Xenon Clear all
Withdrawn Phase 2 Interventional

Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder

NCT02098148
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Xenon, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 20, 2026, 1:23 AM EDT
Active, not recruiting Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Not listed Phase 1 Interventional

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

NCT06271408
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
Drug · Device
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 20, 2026, 1:23 AM EDT
Recruiting Phase 2 Interventional

Using Xe MRI to Guide Radiation Therapy for Lung Cancer

NCT06925295
View directory record Official record
Conditions
Imaging Techniques
Interventions
Xenon MRI, Pulmonary Function Testing, Quality of Life Questionnaire, Medical Research Council Dyspnea score, St. George's Respiratory Questionnaire, Blood Biomarkers
Drug · Diagnostic Test · Other
Lead sponsor
Sean Fain
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment

NCT02478255
View directory record Official record
Conditions
Radiation Injury
Interventions
Hyperpolarized 129-Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 20, 2026, 1:23 AM EDT
Completed Phase 2Phase 3 Interventional

Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI

NCT01832363
View directory record Official record
Conditions
Asthma
Interventions
HXe MRI guided treatment sequence for BT, Standard treatment sequence for BT (control)
Drug · Other
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 20, 2026, 1:23 AM EDT
Withdrawn Not applicable Interventional

Pulmonary Assessment in Thoracic Insufficiency Syndrome Patients

NCT04977830
View directory record Official record
Conditions
Thoracic Insufficiency Syndrome
Interventions
Xenon-129
Device
Lead sponsor
Patrick Cahill, MD
Other
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Active, not recruiting Phase 2 Interventional

Xenon MRI and Progressive ILD

NCT05241275
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Functional Applications of Hyperpolarized 129Xe MRI

NCT01697332
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized 129Xe gas
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 20, 2026, 1:23 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

Technical Development of Xe MRI

NCT07823010
View directory record Official record
Conditions
HSCT, Lung Transplant Recipient
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized Xenon-129 MR Imaging of the Lung

NCT04662658
View directory record Official record
Conditions
E-Cig Use
Interventions
Hyperpolarized Xenon -129 MRI
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 20, 2026, 1:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Patients With and Without Phonotrauma

NCT05625191
View directory record Official record
Conditions
Phonotrauma
Interventions
Acoustic voice analysis, High-speed videoendoscopy
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional Results available

Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism

NCT01458639
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Technegas V SPECT imaging, Xenon-133 Ventilation Planar imaging
Drug
Lead sponsor
Cyclomedica Australia PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Sep 20, 2026, 1:23 AM EDT
Completed Not applicable Interventional Results available

Fluorescent Cholangiography vs White Light for Bile Ducts Identification

NCT02702843
View directory record Official record
Conditions
Cholecystitis, Cholelithiasis
Interventions
Laparoscopic cholecystectomy with Xenon light, Laparoscopic cholecystectomy (fluorescent cholangiography)
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 20, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Hyperpolarized 129Xe MRI of Survivors of COVID-19

NCT04659707
View directory record Official record
Conditions
Covid19
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI

NCT04941573
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 20, 2026, 1:23 AM EDT
Recruiting Phase 2 Interventional

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Completed Phase 3 Interventional

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant

NCT03418090
View directory record Official record
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133XE scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 20, 2026, 1:23 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults

NCT02272049
View directory record Official record
Conditions
Respiratory Disorders
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

NCT04353661
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Azithromycin, HP xenon (¹²⁹XE)
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 20, 2026, 1:23 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

NCT06856525
View directory record Official record
Conditions
Electronic Cigarette Related Lung Damage
Interventions
Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT
Drug · Diagnostic Test
Lead sponsor
Y. Michael Shim, MD
Other
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 20, 2026, 1:23 AM EDT
Active, not recruiting No phase listed Observational

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

NCT02848560
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 12 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 20, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

NCT04071769
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 20, 2026, 1:23 AM EDT